Evidence Level
Moderate
5 Clinical Trials
8 Documented Benefits
3/5 Evidence Score

Pomegranate Extract is concentrated from Punica granatum fruit (juice and peel) and rich in punicalagin, a unique large polyphenol found almost exclusively in pomegranate that's converted by gut bacteria into urolithins (especially urolithin A). The polyphenol profile also includes ellagic acid, anthocyanins, and various other flavonoids. Clinical evidence most strongly supports a modest blood-pressure reduction, with additional research on endothelial function and emerging evidence for cognitive aging support; prostate and other outcomes remain unproven in controlled trials. Effective doses range 500-1,500 mg/day standardized extract. Pomella® (Verdure Sciences) is the most-studied branded form standardized to ≥30% punicalagin. The honest framing: well-evidenced cardiovascular adjunct with multi-pathway mechanisms; the punicalagin to urolithin gut bacteria conversion varies between individuals (estimates range from about 5-25% who make none at all to roughly 60% who made little after a single glass of pomegranate juice); supports cardiovascular health for most users but with individual variation in response.

Studied Dose 500-1,500 mg/day standardized to ≥30% punicalagin.
Active Compound Punicalagin (≥30% in standardized extracts), ellagic acid, anthocyanins, flavonoids.

Benefits

Blood pressure and arterial health

Clinical trials show pomegranate supplementation reduces blood pressure (a modest ~5 mmHg systolic reduction in meta-analysis). A preliminary, unreplicated signal on slowing carotid-artery plaque comes from a single very small trial. Mechanism involves nitric oxide pathway support and reduced vascular oxidative stress.

Endothelial function support

Pomegranate supplementation improves endothelial function and arterial elasticity in adults with cardiovascular risk factors. Effects build over 12+ weeks and support comprehensive cardiovascular health strategies.

Antioxidant capacity

Pomegranate has among the highest antioxidant capacity of common fruits, with documented effects on plasma antioxidant markers. The unique punicalagin profile provides distinct antioxidant activity from other polyphenol sources.

Cognitive aging support (preliminary)

Emerging evidence suggests pomegranate supplementation may support cognitive function in older adults, possibly through urolithin A's mitochondrial effects (see Urolithin A entry). Less robust than the cardiovascular evidence; promising preliminary research.

Cardiometabolic benefits in metabolic syndrome

Trials in adults with metabolic syndrome show pomegranate supplementation modestly improves insulin sensitivity, lipid profiles, and inflammatory markers. Effect sizes consistent with quality cardiovascular polyphenol support.

Punicalagin → urolithin individual variation

Gut bacterial conversion of punicalagin to bioactive urolithins varies between individuals — estimates range from about 5 to 25 percent who make none at all to roughly 60 percent who made little after a single glass of pomegranate juice. Those who don't produce urolithin A naturally may benefit more from direct urolithin A supplementation (Mitopure®) than pomegranate extract.

Lower CRP, IL-6 and TNF-alpha inflammation markers

A meta-analysis of 33 randomized trials of pomegranate products (pooled together, not one standardized extract) found CRP fell by 0.50 mg/L, with IL-6 and TNF-alpha also lower than control. An earlier pooled analysis of 5 juice trials found no significant CRP change, and an industry funded 12 week trial of 740 mg/day extract in 86 adults aged 55 to 70 lowered IL-6 but not CRP or TNF-alpha. These are blood markers only.

Strength recovery after muscle-damaging exercise (small trials)

In a placebo controlled crossover trial in 16 recreationally active men, 9 days of pomegranate extract (POMx) kept elbow flexor strength higher at 48 hours (85.4% vs 78.3% of baseline) and 72 hours after damaging exercise. A juice trial in 36 untrained men (three groups) found no recovery benefit, and a pooled analysis of 10 studies found no change in soreness or most muscle damage markers. Small trials, mixed results.

Mechanism of action

1

Punicalagins and ellagitannin metabolism

Pomegranate punicalagins (~50% of polyphenol content in standardized extracts like Pomella® at ≥30%) are hydrolyzed in the gut to ellagic acid, then converted by Gordonibacter and Eggerthella spp. gut bacteria into urolithins. Urolithin A is the most studied mitophagy-active metabolite. Conversion varies: about 5-25% of people make no urolithin A at all, and in one study roughly 60% made little after a single glass of pomegranate juice — direct urolithin supplementation (Mitopure®) bypasses this variability.

2

Urolithin A and mitophagy

Urolithin A activates mitophagy — the cellular recycling of damaged mitochondria. Mitochondrial dysfunction is causally implicated in muscle aging, sarcopenia, and metabolic decline; direct UA supplementation (Mitopure) has demonstrated muscle strength gains. Direct UA supplementation provides more reliable dosing than relying on gut conversion of pomegranate ellagitannins.

3

Endothelial NO support and ACE inhibition

Pomegranate polyphenols increase endothelial nitric oxide synthase (eNOS) activity and reduce ACE (angiotensin-converting enzyme) activity. These two mechanisms together explain the consistent BP-lowering effect across meta-analyses. Same pharmacological targets as pharmaceutical antihypertensives (ACE inhibitors, NO donors).

4

NF-κB inhibition and antioxidant activity

Punicalagins and urolithin A inhibit NF-κB-mediated inflammatory signaling. Direct antioxidant activity (free radical scavenging, lipid peroxidation reduction). These are the proposed explanation for the CRP, IL-6 and TNF-alpha reductions seen in pooled trial data, although results vary between trials and one earlier pooled analysis found no significant CRP change.

Clinical trials

1
BP Evidence Synthesis

Evidence review and pooled analysis of 8 placebo-controlled clinical trials evaluating pomegranate juice and blood pressure.

2,306 participants

Evidence review and pooled analysis of 8 placebo-controlled clinical trials evaluating pomegranate juice and blood pressure. Pooled effect: SBP -4.96 mmHg (95% CI -7.67 to -2.25, p<0.001), DBP -2.01 mmHg (95% CI -3.71 to -0.31, p=0.021). Effects on SBP remained stable across sensitivity analyses. A subsequent larger meta-analysis (Phytother Res 2024;38:2234-2248) pooling 53 clinical trials confirmed the blood-pressure effect at meta-analytic scale.

2
Carotid IMT

Israeli clinical trial in 19 patients with carotid artery stenosis randomized to 50 mL pomegranate juice/day or placebo × up to 3 years.

19 patients with carotid artery stenosis

Israeli clinical trial in 19 patients with carotid artery stenosis randomized to 50 mL pomegranate juice/day or placebo × up to 3 years. Pomegranate group showed ~30% reduction in carotid intima-media thickness vs ~9% increase in placebo. Critical caveat: very small trial (n=19); dramatic IMT effect has not been consistently replicated in larger trials. The 'pomegranate cures atherosclerosis' marketing rests substantially on this small trial.

3
PSA in Prostate Cancer Recurrence

Open-label single-arm trial in 46 men with rising PSA after prostatectomy or radiation.

46 men with rising PSA after prostatectomy or radiation

Open-label single-arm trial in 46 men with rising PSA after prostatectomy or radiation. 8 oz pomegranate juice/day extended median PSA doubling time from 15 months to 54 months. Critical update: a subsequent randomized, double-blind, placebo-controlled trial (Pantuck 2015) in a similar population was negative — pomegranate extract did not significantly prolong PSA doubling time versus placebo. The uncontrolled single-arm finding has not been independently confirmed. Cancer patients should not replace evidence-based oncology care with pomegranate juice.

4
Urolithin A ATLAS Trial

Randomized double-blind placebo-controlled trial of Urolithin A (Mitopure®, Amazentis SA) in 88 overweight middle-aged adults. 500 or 1,000 mg/day × 4 months.

88 overweight middle

Randomized double-blind placebo-controlled trial of Urolithin A (Mitopure®, Amazentis SA) in 88 overweight middle-aged adults. 500 or 1,000 mg/day × 4 months. +12% muscle strength vs placebo. Failed primary endpoint of peak power output. Significant secondary improvements in 6-minute walk test and aerobic endurance (peak VO2). Industry-funded; supports the polyphenol → urolithin A → mitophagy mechanism but the magnitude in healthy adults is modest.

5
Erectile Dysfunction (Int J Impot Res)

Randomized placebo-controlled crossover trial in 53 men with mild-to-moderate erectile dysfunction.

53 men with mild-to-moderate erectile dysfunction

Randomized placebo-controlled crossover trial in 53 men with mild-to-moderate erectile dysfunction. 8 oz/day pomegranate juice × 4 weeks vs placebo. The primary endpoint did not reach statistical significance (P=0.058) — a non-significant trend in this small pilot crossover. Any IIEF-based signal was directional only; the proposed mechanism aligns with the endothelial NO/vascular pathway, but this trial does not establish an erectile-function benefit.

Side effects and drug interactions

Common Potential side effects

Generally very well tolerated; excellent safety profile across decades of clinical trials.
Mild GI discomfort possible at very high doses of whole fruit extract.
Red urine/stools possible at high doses (harmless pigment — similar to beeturia).
Allergic reactions reported but rare.
Pomegranate juice consumption ~20-30 g sugar per cup — diabetics should prefer extract over juice.

Important Drug interactions

Warfarin — pomegranate inhibits CYP2C9 and CYP3A4; may significantly increase warfarin blood levels. Monitor INR closely.
Statins (atorvastatin, simvastatin, lovastatin) — CYP3A4 inhibition may increase statin levels; monitor for muscle side effects.
Antihypertensive medications — additive blood pressure-lowering effects; monitor BP, especially when initiating.
ACE inhibitors — pomegranate has its own ACE-inhibitory activity; possible additive effect.
CYP3A4 substrates broadly — pomegranate may modestly inhibit; consult prescriber for medications with narrow therapeutic windows metabolized by CYP3A4 (some immunosuppressants, antiarrhythmics, some psychiatric medications).
Pregnancy — pomegranate as food is safe; concentrated supplementation generally safe but limited specific data.
Lactation — pomegranate as food and modest supplementation generally regarded as safe.

Frequently asked questions about Pomegranate Extract

How much pomegranate extract should I take?

Studies use pomegranate juice (about 8 ounces) or extracts standardized to punicalagins and ellagic acid, often around 250 to 1,000 mg per day. Extracts standardized to ellagitannins are common in capsule form.

What is pomegranate extract used for?

Pomegranate is studied for cardiovascular support (including healthy blood pressure), antioxidant activity, exercise performance, and prostate health. Its polyphenols, especially punicalagins, are responsible for much of its activity.

What is the connection between pomegranate and urolithin A?

Gut bacteria convert pomegranate's ellagitannins into urolithin A, a compound studied for mitochondrial and muscle health. Not everyone's gut produces it efficiently, which is why urolithin A is also sold directly as a supplement.

Is pomegranate extract safe?

Pomegranate is generally well tolerated. Like grapefruit, it may interact with certain medications by affecting drug-metabolizing enzymes, so check with your doctor if you take prescriptions, especially blood thinners or blood-pressure drugs.

What is Pomegranate Extract?

Pomegranate Extract is concentrated from Punica granatum fruit (juice and peel) and rich in punicalagin, a unique large polyphenol found almost exclusively in pomegranate that's converted by gut bacteria into urolithins (especially urolithin A).

Does Pomegranate Extract interact with any medications?

Possible interactions include: Warfarin — pomegranate inhibits CYP2C9 and CYP3A4; may significantly increase warfarin blood levels. Monitor INR closely. Statins (atorvastatin, simvastatin, lovastatin) — CYP3A4 inhibition may increase statin levels; monitor for muscle side effects. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Pomegranate Extract?

NutraSmarts rates the evidence for Pomegranate Extract as Moderate (3 out of 5). It is backed by 5 study summaries and 11 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(11 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Sahebkar A, Ferri C, Giorgini P, Bo S, Nachtigal P, Grassi D. Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2017;115:149-161. doi: 10.1016/j.phrs.2016.11.018.PubMedUsed to support: Meta-analysis of RCTs reporting that pomegranate juice significantly lowered both systolic (about -5 mmHg) and diastolic (about -3 mmHg) blood pressure. Primary support for the blood-pressure-lowering claim.
  2. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006;12(13):4018-26. doi: 10.1158/1078-0432.CCR-05-2290.PubMedUsed to support: Early single-arm (uncontrolled) phase II study that reported lengthening of PSA doubling time in men with rising PSA. Generated the prostate-cancer hypothesis but, lacking a placebo arm, is not proof of benefit; presented honestly as preliminary and later not confirmed.
  3. Pantuck AJ, Pettaway CA, Dreicer R, Corman J, Katz A, Ho A, et al. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18(3):242-8. doi: 10.1038/pcan.2015.32.PubMedUsed to support: Negative randomized, double-blind, placebo-controlled trial: pomegranate extract did not significantly prolong PSA doubling time versus placebo (PSADT rose similarly in both arms). Directly refutes the prostate/PSA claim; frame the prostate-cancer story as not proven.
  4. Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004;23(3):423-33. doi: 10.1016/j.clnu.2003.10.002.PubMedUsed to support: Small long-term study in carotid stenosis patients: pomegranate juice reduced carotid intima-media thickness, systolic blood pressure, LDL oxidation, and raised antioxidant/paraoxonase activity. Supports antioxidant and vascular/BP effects; very small (n=10-19, mostly uncontrolled), so treat as preliminary mechanistic support.
  5. Forest CP, Padma-Nathan H, Liker HR. Efficacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction: a randomized, placebo-controlled, double-blind, crossover study. Int J Impot Res. 2007;19(6):564-7. doi: 10.1038/sj.ijir.3901570.PubMedUsed to support: Small pilot crossover trial (n=53) of pomegranate juice in mild-to-moderate erectile dysfunction. The primary IIEF endpoint did NOT reach statistical significance (P=0.058, trend only). Cited to accurately convey that an erectile-function benefit is not established.
  6. Bahari H, Rafiei H, Goudarzi K, Omidian K, Asbaghi O, Kolbadi KSH, Naderian M, Hosseini A. The effects of pomegranate consumption on inflammatory and oxidative stress biomarkers in adults: a systematic review and meta-analysis. Inflammopharmacology. 2023;31(5):2283-2301. doi: 10.1007/s10787-023-01294-x.PubMedUsed to support: Lower inflammation markers. A meta-analysis of 33 RCTs of pomegranate consumption found lower CRP (WMD -0.50 mg/L), IL-6 (-1.24 ng/L), TNF-alpha (-1.96 pg/ml) and MDA, and higher total antioxidant capacity (13 trials).
  7. Sahebkar A, Gurban C, Serban A, Andrica F, Serban MC. Effects of supplementation with pomegranate juice on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2016;23(11):1095-102. doi: 10.1016/j.phymed.2015.12.008.PubMedUsed to support: Counterpoint for the inflammation benefit. A meta-analysis of 5 pomegranate juice RCTs (427 participants) found no significant CRP change (WMD -0.22 mg/l, p=0.061).
  8. Farhat G, Malla J, Vadher J, Al-Dujaili EAS. Effects of Pomegranate Extract on Inflammatory Markers and Cardiometabolic Risk Factors in Adults Aged 55-70 Years: A Randomised Controlled Parallel Trial. Nutrients. 2025;17(7):1235. doi: 10.3390/nu17071235.PubMedUsed to support: Extract-specific inflammation data. A double-blind trial of 740 mg/day pomegranate extract vs maltodextrin placebo for 12 weeks in 86 adults aged 55 to 70 (76 completed): IL-6 and IL-1beta fell, CRP and TNF-alpha changes were not significant, and systolic blood pressure fell 5.22 mmHg. Funded by Euromed S.A.
  9. Trombold JR, Barnes JN, Critchley L, Coyle EF. Ellagitannin consumption improves strength recovery 2-3 d after eccentric exercise. Med Sci Sports Exerc. 2010;42(3):493-8. doi: 10.1249/MSS.0b013e3181b64edd.PubMedUsed to support: Strength recovery. A randomized crossover of POMx pomegranate extract vs placebo for 9 days in recreationally active men. Isometric elbow flexion strength was higher at 48 h (85.4% vs 78.3% of baseline) and 72 h (88.9% vs 84.0%) after eccentric exercise. Serum damage and inflammation markers did not explain the effect.
  10. Lamb KL, Ranchordas MK, Johnson E, Denning J, Downing F, Lynn A. No Effect of Tart Cherry Juice or Pomegranate Juice on Recovery from Exercise-Induced Muscle Damage in Non-Resistance Trained Men. Nutrients. 2019;11(7):1593. doi: 10.3390/nu11071593.PubMedUsed to support: Counterpoint for strength recovery. A randomized double-blind trial in 36 untrained men (tart cherry, pomegranate juice or placebo) found no group differences in strength, soreness, range of motion or CK after eccentric elbow exercise.
  11. Belyani S, Kazeminasab F, Niazi M, Bagheri R, Hesari MM, Rosenkranz SK, Camera DM, Dutheil F. The Effects of Pomegranate Supplementation on Markers of Exercise-Induced Muscle Damage: A Systematic Review and Meta-Analysis. Curr Dev Nutr. 2025;9(2):104560. doi: 10.1016/j.cdnut.2025.104560.PubMedUsed to support: Counterpoint for exercise recovery. A meta-analysis of 10 pomegranate studies found no significant effect on myoglobin, creatine kinase, lactate or muscle soreness. Only lactate dehydrogenase fell immediately after exercise.